- Home
- AVIR vs CBAN Comparison
AVIR vs CBAN Comparison
Compare AVIR & CBAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVIR | CBAN |
|---|---|---|
| Founded | 2012 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.5M | 436.6M |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | AVIR | CBAN |
|---|---|---|
| Price | $4.28 | $19.53 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 261.0K | 253.9K |
| Earning Date | 05-11-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 2.44% |
| EPS Growth | 3.00 | ★ 16.91 |
| EPS | N/A | ★ 0.39 |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | $35.41 |
| Revenue Next Year | N/A | $4.84 |
| P/E Ratio | ★ N/A | $49.74 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $14.63 |
| 52 Week High | $6.45 | $21.61 |
Technical Indicators
Market Signals| Indicator | AVIR | CBAN |
|---|---|---|
| Relative Strength Index (RSI) | 25.10 | 42.10 |
| Support Level | $3.32 | $19.12 |
| Resistance Level | $4.34 | $21.46 |
| Average True Range (ATR) | 0.28 | 0.40 |
| MACD | -0.13 | -0.06 |
| Stochastic Oscillator | 4.35 | 31.67 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.